Published in N Engl J Med on March 08, 1990
Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry (1995) 1.08
Peripheral neuropathies in Waldenström's macroglobulinaemia. J Neurol Neurosurg Psychiatry (2006) 0.97
Extensive demyelinating changes in the peripheral nerves of Crow-Fukase syndrome: a pathological study of one autopsied case. Acta Neuropathol (1992) 0.94
A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry (1997) 0.81
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics (2016) 0.80
Monoclonal IgM from patients with peripheral demyelinating neuropathies cross-react with bacterial polypeptides. Clin Exp Immunol (1994) 0.78
HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets (2014) 0.77
Immunoelectron microscopic localization of monoclonal IgM antibodies in gammopathy associated with peripheral demyelinative neuropathy. Acta Neuropathol (1993) 0.77
Clinical immunology. Postgrad Med J (1991) 0.75
The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet (1999) 4.77
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
ISWI is an ATP-dependent nucleosome remodeling factor. Mol Cell (1999) 2.68
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Coding sequence and growth regulation of the human vimentin gene. Mol Cell Biol (1986) 2.34
The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins. EMBO J (1992) 2.18
Cloning of the mitogen-activated S6 kinase from rat liver reveals an enzyme of the second messenger subfamily. Proc Natl Acad Sci U S A (1990) 2.09
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol (2000) 2.06
Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy. Neurology (1999) 2.01
Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 2.00
Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem (1997) 1.97
Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence. Gastroenterology (1989) 1.93
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem (1998) 1.86
Acf1, the largest subunit of CHRAC, regulates ISWI-induced nucleosome remodelling. EMBO J (2001) 1.81
Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol (1998) 1.80
Prion protein expression in different species: analysis with a panel of new mAbs. Proc Natl Acad Sci U S A (1998) 1.80
Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods (2004) 1.78
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol (1985) 1.72
Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol (2000) 1.71
Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest (1997) 1.70
Multiple sclerosis associated with duplicated CMT1A: a report of two cases. J Neurol Neurosurg Psychiatry (1997) 1.67
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol (2004) 1.65
Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J (2009) 1.62
Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. J Bone Joint Surg Br (2002) 1.58
Association between idiopathic premature ovarian failure and fragile X premutation. Hum Reprod (2000) 1.57
Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest (1995) 1.57
Antithyroid antibodies in the CSF: their role in the pathogenesis of Hashimoto's encephalopathy. Neurology (2003) 1.57
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med (1996) 1.53
Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. Gastroenterology (1990) 1.53
Endothelial cell E- and P-selectin and vascular cell adhesion molecule-1 function as signaling receptors. J Cell Biol (1998) 1.52
Dural arteriovenous fistulas with aggressive course: clinical and angiographic correlations in two patients. Neurol Sci (2005) 1.51
Extracorporeal membrane oxygenation using a centrifugal pump and a servo regulator to prevent negative inlet pressure. Ann Thorac Surg (1997) 1.50
High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes. Ann Thorac Surg (1995) 1.48
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2009) 1.47
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma. J Clin Oncol (2003) 1.46
Selenium status, fatty acids, vitamins A and E, and aging: the Nove Study. Am J Clin Nutr (1994) 1.46
Neoadjuvant chemotherapy for peripheral malignant neuroectodermal tumor of bone: recent experience at the istituto rizzoli. J Clin Oncol (2000) 1.45
Different oxygenators for cardiopulmonary bypass lead to varying degrees of human complement activation in vitro. J Thorac Cardiovasc Surg (1989) 1.45
[ General postural rehabilitation in musculoskeletal diseases: scientific evidence and clinical indications]. Reumatismo (2007) 1.44
Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis (1989) 1.44
Premature translation termination mutations are efficiently suppressed in a highly conserved region of yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J Biol Chem (1994) 1.44
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol (2009) 1.44
Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol (2003) 1.42
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol (2011) 1.40
Absolute alcohol in esophageal vein sclerosis. Gastrointest Endosc (1988) 1.40
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.39
Construction and in vitro functional evaluation of a low-density lipoprotein receptor/transferrin fusion protein as a therapeutic tool for familial hypercholesterolemia. Hum Gene Ther (1999) 1.39
Gene expression profiling in MDS and AML: potential and future avenues. Leukemia (2011) 1.38
Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol (2009) 1.37
Hmg4, a new member of the Hmg1/2 gene family. Genomics (1998) 1.37
Identification of 40 S ribosomal protein S6 phosphorylation sites in Swiss mouse 3T3 fibroblasts stimulated with serum. J Biol Chem (1993) 1.36
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol (2011) 1.36
Structural and functional analysis of a growth-regulated gene, the human calcyclin. J Biol Chem (1987) 1.36
Additional data on the population distribution of human serum albumin genes; three new variants. Ann Hum Genet (1973) 1.35
Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer (2001) 1.34
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. J Med Genet (2004) 1.33
Three cases of human herpesvirus-6 latent infection: integration of viral genome in peripheral blood mononuclear cell DNA. J Med Virol (1993) 1.32
Template-imprinted nanostructured surfaces for protein recognition. Nature (1999) 1.32
Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer (2001) 1.31
Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.31
Activation of complement system by porins extracted from Salmonella typhimurium. Infect Immun (1984) 1.31
Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology (1984) 1.30
Systemic meningococcal disease: a model infection to study acute endotoxinemia in man. Prog Clin Biol Res (1988) 1.30
Proteasomal degradation and N-terminal protease resistance of the codon 145 mutant prion protein. J Biol Chem (1999) 1.30
Antidepressant medications and osteoporosis. Bone (2012) 1.28
Different brain correlates for watching real and virtual hand actions. Neuroimage (2001) 1.28
Studies on the mechanism of metabolic stimulation in polymorphonuclear leucocytes during phagocytosis. I. Evidence for superoxide anion involvement in the oxidation of NADPH2. Biochim Biophys Acta (1975) 1.27
Molecular cloning of a cDNA for a human ADP/ATP carrier which is growth-regulated. J Biol Chem (1987) 1.27
Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut (1997) 1.27
Motoneuron-disease-like disorder after ganglioside therapy. Lancet (1991) 1.26
A familial dysfunction of the eight component of complement (C8). Clin Immunol Immunopathol (1980) 1.26
Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies. J Neurol Sci (1999) 1.25
Differential response of embryonic and fetal myoblasts to TGF beta: a possible regulatory mechanism of skeletal muscle histogenesis. Development (1994) 1.25
Cerebral ischaemia after nifedipine treatment. Br Med J (Clin Res Ed) (1981) 1.25
Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol (1988) 1.25
Degradation of B-Myb by ubiquitin-mediated proteolysis: involvement of the Cdc34-SCF(p45Skp2) pathway. Oncogene (2000) 1.24
Activation of c-myb expression by phytohemagglutinin stimulation in normal human T lymphocytes. Mol Cell Biol (1985) 1.22
A stimulated S6 kinase from rat liver: identity with the mitogen activated S6 kinase of 3T3 cells. EMBO J (1989) 1.22
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo. J Med Virol (1995) 1.22
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem (2000) 1.21
Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex. Arthritis Rheum (1986) 1.20
The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A (2008) 1.20
Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol (1993) 1.19
Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc Natl Acad Sci U S A (1996) 1.19
Two histone fold proteins, CHRAC-14 and CHRAC-16, are developmentally regulated subunits of chromatin accessibility complex (CHRAC). EMBO J (2000) 1.18
Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction. Blood (1991) 1.17
High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol (2002) 1.17